Top

Published in:

01-05-2010

Proton Beam Radiation Therapy for Head and Neck Malignancies

Authors: Steven J. Frank, Ugur Selek

Published in: Current Oncology Reports | Issue 3/2010

Abstract

Proton beam radiation therapy (PBRT) has unique physical properties (e.g., Bragg Peak) that limit the amount of normal tissue irradiated in the head and neck region while maximizing the radiation delivered to the tumor. Radiation therapy is commonly used in both the primary and adjuvant setting for many head and neck malignancies. Limiting the unnecessary radiation to normal tissues within the head and neck region can result in a profound improvement in quality of life during and after treatment. Although PBRT was initially developed in the 1950s, recent technological advances have permitted the development of hospital-based facilities for proton delivery. PBRT has been shown to improve outcomes for patients with sinonasal tumors, chordomas, chondrosarcomas, ocular, and periocular malignancies. Further development of intensity-modulated proton therapy will permit comprehensive treatment for head and neck tumors.

National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: head and neck cancers. NCCN v.1.2009. Accessible at http://www.nccn.org. Accessed January 2010.

Kim GE, Park HC, Keum KC, et al.: Adenoid cystic carcinoma of the maxillary antrum. Am J Otolaryngol 1999, 20:77–84.CrossRefPubMed

Lavertu P, Roberts JK, Kraus DH, et al.: Squamous cell carcinoma of the paranasal sinuses: the Cleveland Clinic experience 1977–1986. Laryngoscope 1989, 99:1130–1136.CrossRefPubMed

Mendenhall WM, Morris CG, Amdur RJ, et al.: Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck. Head Neck 2004, 26:154–162.CrossRefPubMed

Vikram B, Strong EW, Shah JP, et al.: Radiation therapy in adenoid-cystic carcinoma. Int J Radiat Oncol Biol Phys 1984, 10:221–223.PubMed

Garden AS, Weber RS, Morrison WH, et al.: The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int J Radiat Oncol Biol Phys 1995, 32:619–626.CrossRefPubMed

Katz TS, Mendenhall WM, Morris CG, et al.: Malignant tumors of the nasal cavity and paranasal sinuses. Head Neck 2002, 24:821–829.CrossRefPubMed

Takeda A, Shigematsu N, Suzuki S, et al.: Late retinal complications of radiation therapy for nasal and paranasal malignancies: relationship between irradiated-dose area and severity. Int J Radiat Oncol Biol Phys 1999, 44:599–605.CrossRefPubMed

Waldron JN, O’Sullivan B, Warde P, et al.: Ethmoid sinus cancer: twenty-nine cases managed with primary radiation therapy. Int J Radiat Oncol Biol Phys 1998, 41:361–369.PubMed

10.

Parsons JT, Bova FJ, Fitzgerald CR, et al.: Severe dry-eye syndrome following external beam irradiation. Int J Radiat Oncol Biol Phys 1994, 30:775–780.PubMed

11.

Chen AM, Daly ME, Bucci MK, et al.: Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement? Int J Radiat Oncol Biol Phys 2007, 69:141–147.PubMed

12.

Daly ME, Chen AM, Bucci MK, et al.: Intensity-modulated radiation therapy for malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys 2007, 67:151–157.PubMed

13.

Hoppe BS, Stegman LD, Zelefsky MJ, et al.: Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting—the MSKCC experience. Int J Radiat Oncol Biol Phys 2007, 67:691–702.PubMed

14.

Chan AW, Pommier P, Deschler DG, et al.: Change in patterns of relapse after combined proton and photon irradiation for locally advanced paranasal sinus cancer. Int J Radiat Oncol Biol Phys 2004, 60:S320.CrossRef

15.

Pommier P, Liebsch NJ, Deschler DG, et al.: Proton beam radiation therapy for skull base adenoid cystic carcinoma. Arch Otolaryngol Head Neck Surg 2006, 132:1242–1249.CrossRefPubMed

16.

Weber DC, Chan AW, Lessell S, et al.: Visual outcome of accelerated fractionated radiation for advanced sinonasal malignancies employing photons/protons. Radiother Oncol 2006, 81:243–249.CrossRefPubMed

17.

Rosenthal DI, Barker JL JR, El-Naggar Ak, et al.: Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer 2004, 101:2567–2573.CrossRefPubMed

18.

Nishimura H, Ogino T, Kawashima M, et al.: Proton-beam therapy for olfactory neuroblastoma. Int J Radiat Oncol Biol Phys 2007, 68:758–762.PubMed

19.

Chera BS, Malyapa R, Louis D, et al.: Proton therapy for maxillary sinus carcinoma. Am J Clin Oncol 2009, 32:296–303.CrossRefPubMed

20.

Kozak KR, Adams J, Krejcarek SJ, et al.: A dosimetric comparison of proton and intensity-modulated photon radiotherapy for pediatric parameningeal rhabdomyosarcomas. Int J Radiat Oncol Biol Phys 2009, 74:179–186.PubMed

21.

Lee N, Xia P, Quivey JM, et al.: Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002, 53:12–22.CrossRefPubMed

22.

Wolden SL, Chen WC, Pfister DG, et al.: Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 2006, 64:57–62.PubMed

23.

Kam MK, Teo PM, Chau RM, et al.: Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: The Hong Kong experience. Int J Radiat Oncol Biol Phys 2004, 60:1440–1450.PubMed

24.

Kam MK, Leung SF, Zee B, et al.: Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007, 25:4873–4879.CrossRefPubMed

25.

Noel G, Boisserie G, Dessard-Diana B, et al.: Comparison of dose-volume histograms of two-conformal irradiation techniques used for treatment of T2N0M0 nasopharyngeal cancer, one with association of photons and protons with photons alone. Cancer Radiother 2002, 6:337–348.PubMed

26.

Widesott L, Pierelli A, Fiorino C, et al.: Intensity-modulated proton therapy versus helical tomotherapy in nasopharynx cancer: planning comparison and NTCP evaluation. Int J Radiat Oncol Biol Phys 2008, 72:589–596.PubMed

27.

Lin R, Slater JD, Yonemoto LT, et al.: Nasopharyngeal carcinoma: repeat treatment with conformal proton therapy—dose-volume histogram analysis. Radiology 1999, 213:489–494.PubMed

28.

Brown AP, Urie MM, Chisin R, et al.: Proton therapy for carcinoma of the nasopharynx: a study in comparative treatment planning. Int J Radiat Oncol Biol Phys 1989, 16:1607–1614.PubMed

29.

Patel S, Adams JA, Chan AW: Nasopharynx. In Proton and Heavier Charged Particle Radiotherapy. Edited by Delaney T, Kooy H. Baltimore, MD: Lippincott Williams and Wilkins; 2007:98–107.

30.

Selek U, Garden AS, Morrison WH, et al.: Radiation therapy for early-stage carcinoma of the oropharynx. Int J Radiat Oncol Biol Phys 2004, 59:743–751.PubMed

31.

Fein DA, Lee WR, Amos WR, et al.: Oropharyngeal carcinoma treated with radiotherapy: a 30-year experience. Int J Radiat Oncol Biol Phys 1996, 34:289–296.PubMed

32.

Fein DA, Mendenhall WM, Parsons JT, et al.: Pharyngeal wall carcinoma treated with radiotherapy: impact of treatment technique and fractionation. Int J Radiat Oncol Biol Phys 1993, 26:751–757.PubMed

33.

Gwozdz JT, Morrison WH, Garden AS, et al.: Concomitant boost radiotherapy for squamous carcinoma of the tonsillar fossa. Int J Radiat Oncol Biol Phys 1997, 39:127–135.PubMed

34.

Chao KS, Ozyigit G, Blanco AI, et al.: Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys 2004, 59:43–50.PubMed

35.

Garden AS, Morrison WH, Wong PF, et al.: Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2007, 67:438–444.PubMed

36.

de Arruda FF, Puri DR, Zhung J, et al.: Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 2006, 64:363–373.PubMed

37.

Lee NY, de Arruda FF, Puri DR, et al.: A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006, 66:966–974.PubMed

38.

Slater JD, Yonemoto LT, Mantik DW, et al.: Proton radiation for treatment of cancer of the oropharynx: early experience at Loma Linda University Medical Center using a concomitant boost technique. Int J Radiat Oncol Biol Phys 2005, 62:494–500.PubMed

39.

Tai PT, Craighead P, Bagdon F: Optimization of radiotherapy for patients with cranial chordoma. A review of dose-response ratios for photon techniques. Cancer 1995, 75:749–756.CrossRefPubMed

40.

Gay E, Sekhar LN, Rubinstein E, et al.: Chordomas and chondrosarcomas of the cranial base: results and follow-up of 60 patients. Neurosurgery 1995, 36:887–896; discussion 896–887.CrossRefPubMed

41.

Debus J, Schulz-Ertner D, Schad L, et al.: Stereotactic fractionated radiotherapy for chordomas and chondrosarcomas of the skull base. Int J Radiat Oncol Biol Phys 2000, 47:591–596.CrossRefPubMed

42.

Zorlu F, Gurkaynak M, Yildiz F, et al.: Conventional external radiotherapy in the management of clivus chordomas with overt residual disease. Neurol Sci 2000, 21:203–207.CrossRefPubMed

43.

Munzenrider JE, Liebsch NJ: Proton therapy for tumors of the skull base. Strahlenther Onkol 1999, 175:57–63.CrossRefPubMed

44.

Hug EB, Loredo LN, Slater JD, et al.: Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg 1999, 91:432–439.CrossRefPubMed

45.

Noel G, Feuvret L, Calugaru V, et al.: Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. Acta Oncol 2005, 44:700–708.CrossRefPubMed

46.

•• Ares C, Hug EB, Lomax AJ, et al.: Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. Int J Radiat Oncol Biol Phys 2009, 75:1111–1118. In this study, 5-year local control rates were 81% for chordomas and 94% for chondrosarcomas and the freedom from high-grade (grade 3 and 4) toxic effects was 94%.PubMed

47.

• Amichetti M, Cianchetti M, Amelio D, et al.: Proton therapy in chordoma of the base of the skull: a systematic review. Neurosurg Rev 2009, 32:403–416. This article provides a comprehensive review of the outcomes of skull base chordomas using proton beam radiation therapy.CrossRefPubMed

48.

Miralbell R, Cella L, Weber D, Lomax A: Optimizing radiotherapy of orbital and paraorbital tumors: intensity-modulated X-ray beams vs. intensity-modulated proton beams. Int J Radiat Oncol Biol Phys 2000, 47:1111–1119.PubMed

49.

•• Brada M, Phijls-Johnannesma M, Ruysshcer D: Proton therapy in clinical practice: current clinical evidence. J Clin Oncol 2007, 25:965–970. This article reports that, for patients presenting with ocular melanoma, seven studies (n = 7355) showed a 5-year cause-specific survival rate of 85%, with a 90% eye-preservation rate and a 97% local control rate.CrossRefPubMed

Title: Proton Beam Radiation Therapy for Head and Neck Malignancies
Authors: Steven J. Frank
Ugur Selek
Publication date: 01-05-2010
Publisher: Current Science Inc.
Published in: Current Oncology Reports / Issue 3/2010
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-010-0089-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2010

KRAS Testing and Its Importance in Colorectal Cancer

The Emergence of Endoscopic Head and Neck Surgery

Current and Emerging Treatment Strategies for Anal Cancer

Prognostic and Predictive Factors in the Targeted Therapy Era: Filling in the Blanks

Novel Perspectives for the Treatment of Gastric Cancer: From a Global Approach to a Personalized Strategy

B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant Melanoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer